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Abbreviations 
 
BVMD – Best Vitelliform Macular Dystrophy  
ARB – Autosomal Recessive Bestrophinopathy   
CNV – Choroidal Neovascularization  
BCVA – Best corrected visual acuity 
dHPLC – denaturing high-performance liquid chromatography 
EOG – Electro-oculogram   
mfERG – multifocal Electroretinography   
OCT – Optical Coherence Tomography  
RPE – retinal pigment epithelium  
ISCEV – International Society for Clinical Electrophysiology of Vision 
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Abstract 
 
Purpose: to evaluate genotype-phenotype correlations in the BEST1 mutation 
spectrum and check whether the Portuguese findings fit the continuum observed in other 
populations. 
Methods: twenty four affected individuals and thirteen controls from eleven 
unrelated families (twenty four males, thirteen females, ages between 10 and 59 years) 
were characterized by mutation analysis with a combination of denaturing high-performance 
liquid chromatography (dHPLC) and direct sequencing, and clinical examination. 
Electrophysiology (EOG and mfERG) and optical coherence tomography (OCT) were 
additionally performed whenever possible. 
Results: We identified four novel BEST1 mutations in four unrelated families (three in 
patients with Best disease and one in ARB patients). In BVMD patients, we found 3 causative 
sequence changes in BEST1 gene. Two families with BVMD and a case of multifocal Best had 
no mutations in BEST1. According to mfERG measurements there is a significant peripheral 
impairment of retinal function in BVMD. Furthermore, changes in thickness of the 
neurosensory retina, as measured by OCT, and reduced mfERG responses were also 
indicators of early loss in BVMD and often occurred even with preserved visual acuity. There 
was a substantial reduction in mfERG amplitude responses in BVMD and ARB patients.  
Conclusions: Several novel BEST1 mutations were found and genotype-phenotype 
correlations were addressed. EOG was abnormal or subnormal in almost all patients even 
when visual acuity is unaltered. ARB patients showed lower Arden ratio on EOG than BVMD 
ones. The lesion area did not depend on the mutation and did not correlate with visual 
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acuity. Generally, lower visual acuity was associated with advanced BVMD stages, mostly 
with the atrophic stage. Disease duration does not correlate with mfERG measurements. 
Resumo 
 
Objectivo: avaliar correlações genótipo-fenótipo no espectro de mutações do gene 
BEST1 e determinar se os achados na população portuguesa são concordantes com o 
observado noutras populações. 
 Métodos: Foram caracterizados vinte e quatro indivíduos afectados e treze normais, 
pertencentes a onze famílias diferentes (vinte e quatro do sexo masculino e treze do sexo 
feminino, com idades compreendidas entre 10 e 59 anos). Foi realizada uma avaliação clínica 
e molecular, através da análise de mutações com dHPLC e por sequenciação directa. A 
análise fenotípica incluiu a realização de testes anatomo-funcionais, incluindo electro-
oculograma (EOG), electroretinograma multifocal (mfERG) e tomografia de coerência óptica 
(OCT). 
Resultados: Foram identificadas quatro mutações novas em quatro famílias 
independentes (três com doença de Best e uma com bestrofinopatia autossómica recessiva). 
Em duas das famílias com doença de Best e num caso de Best multifocal não foram 
identificadas mutações no gene BEST1. De acordo com os dados do ERG multifocal, existe 
um aumento significativo da função retiniana periférica nos doentes com BVMD. Outros 
indicadores de lesão precoce na doença de Best são as alterações na espessura da retina 
neurosensorial, medida através de OCT, e a diminuição das respostas no ERG multifocal. 
Estas alterações podem estar presentes mesmo quando a acuidade visual está preservada. 
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Existe uma diminuição significativa da amplitude das respostas tanto nos doentes com 
BVMD como nos doentes com ARB. 
Conclusões: Foram identificadas novas mutações que permitem inferir correlações 
genótipo-fenótipo. O EOG revela-se anormal ou subnormal na maioria dos doentes, mesmo 
quando a acuidade visual é normal. Os doentes com ARB apresentam índices de Arden mais 
baixos do que os doentes com BVMD. A área da lesão não está relacionada com a mutação 
subjacente nem com a acuidade visual. Em regra, uma acuidade visual baixa está associada a 
estadios mais avançados da doença, principalmente ao estadio atrófico. A duração da 
doença não está relacionada com o grau de alterações no ERG multifocal. 
 
Keywords Best Vitelliform Macular Dystrophy · Autosomal Recessive Bestrophinopathy · 
multifocal Best · retinal pigmented epithelium · BEST1 gene · Arden ratio · multifocal 
electroretinogram · optical coherence tomography 
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Introduction 
 
Best Disease or Best Vitelliform Macular Dystrophy (BVMD) is an autosomal 
dominant (AD) disorder, with incomplete penetrance and variable phenotypic expressivity 
(Boon et al., 2009). It is one of the most common retinal dystrophies and it predominantly 
affects the macula (Boon et al., 2009).    
BVMD was first described in 1905 by Friedrich Best, a German Ophthalmologist. This 
macular dystrophy usually begins during the first or second decade of life, but it is highly 
variable, with mean in the fourth decade (Mohler and Fine, 1981; Seddon et al., 2003; 
Wabbels et al., 2006). Most cases show a solitary lesion in the macula (unifocal), others have 
multifocal lesions that confine to the posterior pole (Querques et al., 2008). 
Decreased visual acuity may be the first symptom describe by BVMD patients. Other 
symptoms are metamorphopsia, photophobia, and loss of night vision. Mild to marked 
hypermetropia is a common associated finding (Boon et al., 2009). It was shown that there is 
a high correlation between patient age and visual acuity (Fishman et al, 1993; Boon et al., 
2009). 
Many classifications have been proposed, based on ophthalmoscopic aspect of the 
lesions. Friedrich Best classification proposes five stages: previtelliform stage, in which the 
fovea is normal or shows discrete RPE alterations; vitelliform stage, with a well 
circumscribed macular lesion, completely filled by yellowish material, resembling an egg 
yolk; pseudohypopyon stage, with yellow material accumulated inferiorly; vitelliruptive 
stage, in which the previously confluent vitelliform material breaks up; and the atrophic 
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stage, with final chorioretinal atrophy (Querques et al., 2008). Gass, in 1997, also described 
a sixth stage: cicatricial stage and/or neovascular stage, in which subsequent scarring 
appears due to choroidal neovascularization (Boon et al., 2009). Some BVMD patients can 
show a different stage in each eye and many lesions simultaneously show characteristics of 
different BVMD stages (Boon et al., 2009). Even in the sixth stage, despite central starring, 
patients often retain a good visual acuity (Chung et al., 2001). 
Choroidal neovascularization (CNV) is often difficult to recognize in BVMD lesions, but 
it occurs in 2-9% of cases (Chung et al., 2001; Boon et al., 2009). The presence of CNV may 
be inferred when there is subretinal hemorrhage or a grayish-green scar within a lesion 
(Chung et al., 2001; Boon et al., 2009). CNV in BVMD lesions often occurs after ocular 
trauma, according to some reports (Chung et al., 2001; Boon et al., 2009).  
BVMD was the first disease reported to have a cause-effect correlation with 
mutations in the BEST1 gene (Petrukhin et al., 1998). The BEST1 gene maps to chromosome 
11q12-q13; it is mainly expressed in the retinal pigmented epithelium (RPE) but also in 
kidney, spinal cord, brain and testis (Boon et al., 2009; Petrukhin et al., 1998). BEST1 gene 
encodes the bestrophin-1 protein, which is located in the basolateral plasma membrane of 
the RPE. It may also be found in the intracellular space (Boon et al., 2009). This protein is 
involved in the transport of Ca2+/Cl- through the basolateral plasma membrane of RPE and 
also modulates activity of voltage gated L-type Ca2+ channels (Wabbels et al., 2006). The 
normal function of this channel depends upon appropriate bestrophin oligomerisation, thus 
mutations in the BEST1 gene will lead to various extent of disease severity and may affect 
penetrance (Wabbels et al., 2006). 
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Posterior studies also found BEST1 gene mutations in patients with Adult-onset 
Foveomacular Vitelliform Dystrophy (AFVD). In addition, BEST1 mutations can also cause 
ADVIRC (AD Vitreoretinochoroidopathy), ADMRCS Syndrome (Microcornea, rod-cone 
dystrophy, early-onset cataract and posterior staphyloma) and ARB (Autosomal Recessive 
Bestrophynopathy) (Boon et al., 2009; Burgess et al., 2008). 
Autosomal recessive bestrophinopathy (ARB) is a distinct retinal disorder that results 
from biallelic mutations in BEST1. It is associated with central visual loss, a characteristic 
retinopathy, absent electro-oculogram light rise and a reduced electroretinogram. 
Heterozygote patients have no clinical or electrophysiological abnormalities (Burgess et al., 
2008). 
The aims of this paper are to clinically and genetically characterize eleven 
independent Portuguese families carrying the diagnosis of either BVMD or ARB, to perform a 
complete clinical evaluation which includes structural (OCT), and electrophysiological 
(multifocal ERG and EOG) studies of all affected individuals and their relatives. Molecular 
genetics of these cases were performed elsewhere as a part of an international 
collaboration. We also propose to evaluate possible genotype-phenotype correlations in the 
BEST1 mutation spectrum, and check whether the Portuguese findings fit the continuum 
observed in other populations.  
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Materials and Methods 
 
Patient and control population 
Thirty seven individuals from eleven unrelated families (twenty four males, thirteen 
females, ages between 10 and 59 years) were included in this study. Twenty four are 
affected, and thirteen are healthy controls. All affected individuals are followed at the 
Centre for Hereditary Eye Diseases of the Department of Ophthalmology, University Hospital 
of Coimbra. Probands and affected family members presented at our clinic mostly due to 
visual impairment (loss of central vision) or funduscopic changes that fit the clinical diagnosis 
of Best disease, autosomal recessive bestrophinopathy, or multifocal Best. 
All individuals included in the study were informed about its objectives and 
volunteered to participate. Informed consent was obtained from all subjects according to 
the tenets of the declaration of Helsinki. The study was approved by the Ethics Committee of 
the University Hospital of Coimbra. 
 
Clinical Examination 
Ophthalmic examination included assessment of best corrected visual acuity (BCVA) 
after manifest or cycloplegic refraction, slit-lamp examination and fundus examination using 
a non-contact 78-diopter lens. Fundus photography was performed with a TOPCON TRC 50X 
(Topcon Optical, Tokyo, Japan).  
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Electrophysiology (EOG and ERG) 
Electrooculograms (EOG) were recorded in all patients according to the ISCEV-
standard using a Nicolet Spirit-System (Nicolet Biomed, USA). According to our normative 
database Arden ratios were rated pathologic below 1.80. Eye movements were monitored 
during recording and the original waveforms were displayed. The amplitude of collection 
was automatically measured by the system and plotted. This was checked for plausibility. 
Multifocal ERGs (mfERGs) were recorded using DTL fiber electrodes, after a light 
adaptation period of 10 minutes and pupil dilation with tropicamide, before fundus 
photography, with a commercial system (RETIscan System; Roland Consult) (Kutschbach, 
1997). Refractive errors were corrected in relation to the viewing distance. The stimulus 
used in the mfERG consisted of 61 hexagons covering a visual field of up to 30° and 
presented on a 20-inch monitor at a viewing distance of 33 cm. Luminance was 120 cd/m2 
for white hexagons and approximately 1 cd/m2 for black hexagons, resulting in a Michelson 
contrast of 99%. The hexagonal areas increased with eccentricity to compensate for local 
differences in signal amplitude because of differences in cone density across the retina 
(leading to a fourfold change in hexagon area size). Each hexagon was temporally modulated 
between light and dark according to a binary m-sequence (frame rate, 60 Hz). Observers 
were instructed to fixate a small black cross in the center of the stimulus. Fixation was 
continuously checked by means of online video-monitoring during the approximately 8-
minute recording sessions. To improve fixation stability, sessions were broken into 47-
second segments; eight trials were recorded in total. Signals were amplified with a gain of 
100,000 and were band-pass filtered (5–300 Hz). 
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Reference and ground electrodes were attached to the ipsilateral outer canthus and 
forehead, respectively. The surface electrode impedance was less than 10 k_. Analyses were 
performed with the system software (RETIscan; Roland Consult) and standard statistical 
packages. First-order kernels were used for mfERG analysis because of their close correlation 
with the function of the outer retina (Hood, 1997). The obtained local ERGs responses were 
normalized by the area of stimulus delivery to obtain a density response (nV/deg2). For each 
hexagon, the peak amplitude of P1—defined as the difference between N1 and P1 
amplitudes—the N1 peak, and the implicit time of P1 component were computed. To easily 
evaluate spatial differences of the local ERG responses, responses from the 61 elements 
were divided into averages of five concentric rings around the fovea. 
 
Optical Coherence Tomography (OCT) 
OCT was performed with commercially available equipment in fourteen BVMD 
patients, three ARB patients and two with multifocal Best. We used an OCT device (Stratus 
OCT; Carl Zeiss Meditec, Dublin, CA) to obtain cross-sectional images centered in the 
macula,26 with axial resolution of 10 _m or less, transversal resolution of 20 _m, and 
longitudinal scan range of 2 mm. With this OCT device (Stratus OCT; Carl Zeiss Meditec), six 
radial line scans 6 mm in length and 128 A-scans 30° apart were scanned in 1.92 seconds, 
and a nine-region retinal thickness map was obtained by segmenting the retina from other 
layers with an algorithm detecting the edge of the RPE and the photoreceptor layer. 
Macular retinal thickness was calculated by computing the distance between the 
signal from the vitreoretinal interface and the signal from the anterior boundary of the RPE. 
Retinal thickness was presented as a nine-region thickness map showing the interpolated 
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thickness for each area, with a central circle of 500 _m radius (ring 0) and two outer circles 
with radii of 1500 _m (ring 1) and 3000 _m (ring 2). The interpolated thickness was displayed 
using a false color scale, in which bright colors (red and white) corresponded to thickened 
areas and darker colors (blue and black) were assigned to thinner areas. 
 
Molecular genetic analysis  
Genomic DNA was extracted using an automated DNA extractor (BioRobot EZ1, 
Qiagen, Hilden, Germany). The 11 exons of gene BEST1 were PCR-amplified using previously 
described primers and conditions (Petrukhin et al., 1998). To detect sequence changes, all 
exons of BEST1 were screened by dHPLC using a WAVE TM DNA Fragment Analysis System 
(Transgenomic). The PCR amplicons from control DNA and test DNA were combined in 1:1 
ratio and were loaded (5μl) on a C18 reserved-phase column (DNA Sep
TM column; 
Transgenomic). The column mobile phase consisted of an acetonitrile gradient formed by 
mixing buffers A and B (WAVE OptimizedTM; Transgenomic). The flow rate was set at 0.9 
ml/min and DNA was detected at 260 nm. For each amplicon, three optimum temperatures 
for hetero- and homodimer detection were determined empirically. The chromatograms 
obtained with the control and test samples were compared for the peak number and shape, 
for each temperature. All abnormal heteroduplexes obtained were, then, sequenced. 
Amplification products were purified with QIA-quick Gel Extraction Kit (Qiagen). Sequencing 
reactions were performed using the 4-dye terminator cycle sequencing ready reaction kit 
(BigDye DNA Sequencing Kit, Applied Biosystems, Foster City, CA). Sequence products were 
purified through fine columns (Sephadex G-501, Princetown Separations, Adelphia, NJ) and 
resolved in an ABI Prism 3130 (Applied Biosystems). In those cases, in which no mutation 
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was detected using dHPLC screening, all BEST1 exons were directly sequenced to guarantee 
that all sequence changes were identified.  
 
Results 
 
Clinical and molecular findings 
The individual clinical details are summarized in Table I (BVMD patients), II (ARB 
patients) and III (multifocal Best patients) and the pedigrees are shown in Figure 1 – 7. 
Representative images from fundus photography of BVMD and ARB patients are shown in 
Figure 8 and 9.  
We identified the causative BEST1 mutations in 4 families of the 11 tested families (3 
BVMD families and 1 ARB family). All mutations are summarized in Tables I and II, 
respectively. All were novel missense mutations located in exons 2 and 6. The novel 
sequence changes were classified as disease-causing based on the following criteria: 
segregation within the family, location within regions known to be frequently affected by 
mutations (‘hotspot’ regions) and degree of conservation in the bestrophin-related family 
members. For consistency, we used the homologies suggested by Marquardt and colleagues 
(Marquardt et al., 1998) for multiple sequence alignment of predicted human BEST1 with 
putative proteins from C..elegans of 47.7 (P34577), 73.8 (P34672) and 47.8 kDa (Q09379) as 
well as the partial EST-encoded sequences from D. melanogaster (AA817295), Mus musculus 
(AA497726) and human (AA621745, AA777061). 
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Fig. 1 – 4: Representative pedigrees of patients with classic Best; Fig. 5: representative 
pedigree of a family with ARB; Fig. 6 – 7: Representative pedigrees of two independent 
patients with multifocal Best. 
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A - V.F.C. (male, Family C.)  
B - L.G. (male, Family G.)  
Fig. 8 (A and B) – Best patients. Fundus photographs show: a well-demarcated, yellow and 
round lesion in both eyes (A); an egg-yolk lesion, evolving to an atrophic area inferior to fovea 
(OD) and a little atrophic area inferior to fovea (OS) (B). 
B - L.G. (male, Family G.)  
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a - P.D.G. (male, Family D.G.)  
Fig. 9 (a and b) – ARB patients. Fundus photographs show: a stage II lesion inferior to fovea (OD) 
and an atrophic lesion inferior to fovea (OS) (a); no significant changes (OU) (b). 
b - B.D.G. (female, Family D.G.)  
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We detected a novel amino acid change (Val9Glu) in BEST1 gene in 7 patients from a 
Portuguese BVMD family (Fig. 3 and Table I); this change was not present in either the 
tested unaffected family members or in the 102 chromosomes from healthy Portuguese 
controls. This novel T>A transversion at nucleotide 26 – V9E - replaces an amino acid residue 
for another of different nature - valine (nonpolar, neutral, hydropathy index (HI) of 4.2) for 
glutamic acid (polar, acidic and HI of 3.5). All BVMD patients with V9E mutation had an 
abnormal EOG, BCVA ranging from 2/10 to 10/10, variable macular degeneration ranging 
from mild stage I yellowish deposits to cicatricial changes that may be seen early in the 
disease process. Multifocal ERG was significantly altered in all affected family members, but 
did not correlate linearly with BCVA. For all affected members, the age of onset ranged from 
5 to 15 years. 
Another novel mutation found in exon 2 of BEST1: Glu35Lys (Table I) was detected in 
a single affected individual without prior family history of retinal disease. This novel 
substitution was not detected in 102 Portuguese healthy controls. The patient has an early 
disease onset (14 years), significantly reduced visual acuity, a decreased Arden ratio on EOG 
and an altered OCT. 
Two novel missense mutations were found in exon 6 of BEST1: Glu213Gly and 
Leu234Val. The novel sequence change c.638A>G leading to the amino acid substitution 
Glu213Gly was found in homozygous state (hh) in three members of this ARB family but 
neither in their unaffected sister (Fig. 5, II:3) nor in 102 control chromosomes. Those 
patients (Family D.G.; Fig. 5), with no other causative sequence change, were severely 
affected, had an abnormal EOG and the onset of visual loss between 24 and 30 years. The 
son and daughter of two of them were confirmed to be carriers (Hh) and showed no sign of 
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macular degeneration by ophthalmological examination. However, the girl’s EOG and mfERG 
were found to be subnormal, even in the absence of other clinical findings.  
The novel missense mutation - Leu234Val - was segregated in a BVMD Portuguese 
family (Family C.) in which no other mutation in BEST1 was found (Fig. 4). This novel 
substitution has not been detected in genomic DNA samples from 102 healthy controls of 
unrelated origin. Thus, Leu234Val is considered to be causative of BVMD.  
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Family 
Patient 
Sex 
Age at 
onset 
(years) 
Age at 
examination 
DNA Visual Acuity 
OD           OS 
Biom. Fundus EOG 
Arden-
ratio 
OD/OS 
mfERG OCT 
Family A 
(P.A.) 
female  
NA 36 No mutations in 
BEST1  
8/10      8/10 N OU: central 
yellowish deposits 
stage I 
1,42/1,53 Central 
dysfunction till 
~15°, Max peaks: 
~65nV/deg
2
(OD) 
and 
49nV/deg
2
(OS) 
OCT: 
OD  Z0=230/ 
Z1=233/ Z2=193  
OS  Z0=235/ 
Z1=240/ Z2=197 
Family A 
(A.A.) 
male 
7 10 No mutations in 
BEST1  
8/10      8/10 N OD: yellow, round 
lesion with ~250 
µm 
OS: N 
1,31/ 1,04 Central 
dysfunction till 
~15°, Max peaks: 
~35nV/deg
2
(OS) 
and 
11nV/deg
2
(OD) 
OCT: 
OD  Z0=201/ 
Z1=260/ Z2=208  
OS  Z0=198/ 
Z1=260/ Z2=210 
Family G 
(J.G.) 
male 
40 56 No mutations in 
BEST1  
10/10  10/10 Pseudo-
faquia OU 
OD: N 
OS: cicatricial 
perifoveal lesion 
 
 
 
1,69/ 1,23 
 
Altered OU, Max 
peaks: 45nV/deg
2
 
decentered 10° 
(OD) and central 
peak of 
38,1nV/deg
2
 (OS) 
OCT: 
OD  Z0=265/ 
Z1=294/ Z2=234 
OS  Z0=307/ 
Z1=299,25/ 
Z2=242 
Family G 
(L.G.) 
male 
 
7 
 
22 
No mutations in 
BEST1 
 
8/10    10/10 
 
N 
OD: egg-yolk lesion 
evolving to an 
atrophic area 
inferior to fovea 
OS: little atrophic 
area inferior to 
fovea 
1,43/ 1,46 Altered OU, Max 
peaks: 51 
nV/deg
2
 
decentered 10° 
(OD) and central 
peak of 
55nV/deg
2
(OS) 
OCT: 
OD  Z0=335/ 
Z1=312,75/ 
Z2=289,25 
OS  Z0=198/ 
Z1=260,5/ 
Z2=263,25 
Family AL 
(O.AL.) 
male 
5-15 35 Novel BEST1 
mutation Val9Glu 
 
3/10         9/10 N OD: scrambled egg/ 
atrophy in macula 
OS: atrophic central 
macular lesion 
1,38/1,41 Altered OU, Max 
peaks: 21,1 
nV/deg
2
 (OD) and 
23,6 nV/deg
2
 (OS) 
OCT: 
OD  Z0=147/ 
Z1=211/ Z2=240 
OS  Z0=268/ 
Z1=229/ Z2=231 
 
Table I – Clinical data and mutations involved for the patients with Best disease presented in this study 
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Family AL 
(M.R.AL.) 
female 
5-15 44 Novel BEST1 
mutation Val9Glu 
 
4/10        3/10 N OU: central 
atrophic macular 
lesions with 
pigmented changes 
1,50/1,51 Altered OU, Max 
peaks: 22,4 
nV/deg
2
 (OD) and 
31,3 nV/deg
2
 
(OS), decentered 
10° 34,1 nV/deg2 
(OD) 
NA 
 
Family AL 
(L.C.) 
male 
5-15 36 Novel BEST1 
mutation Val9Glu 
 
   5/10       5/10    N OU: central lesions 
(3mm) with 
cicatricial changes 
1,31/1,27 Altered OU, Max 
peaks: 28,8 
nV/deg
2
 (OD) and 
27,4 nV/deg
2
 
(OS); 58 nV/deg
2
 
decentered 10°  
(OD) 
OCT: 
OD  Z0=359/ 
Z1=347/ Z2=251 
OS  Z0=466/ 
Z1=418/ Z2=241 
Family AL 
(A.S.AL.) 
female 
5-15 25 Novel BEST1 
mutation Val9Glu 
 
8/10     8/10 N OU: central 
yellowish deposits 
stage I 
1,53/1,46 Altered OU, Max 
peaks: 66,4 
nV/deg
2
 (OD) and 
79,1 nV/deg
2
 (OS) 
NA 
 
Family AL 
(B.AL.) 
male 
5-15 24 Novel BEST1 
mutation Val9Glu 
 
5/10    5/10 N OU: central lesions 
with atrophic areas 
and scarring 
1,39/1,43 Altered OU, Max 
peaks: 26,7 
nV/deg
2
 (OD) and 
33,3 nV/deg
2
 (OS) 
OCT: 
OD  Z0=300/ 
Z1=302/ Z2=222 
OS  Z0=351/ 
Z1=356/ Z2=210 
Family AL 
(H.AL.) 
male 
7 14 Novel BEST1 
mutation Val9Glu 
 
10/10      2/10 N OD: central egg-
yolk lesion (2mm) 
OS: scrambled egg 
and atrophic 
scarring 
1,52/1,46 Altered OU, Max 
peaks: 31,1 
nV/deg
2
  and 
29,5nV/deg
2
 
decentered 10° 
(OU) 
OCT: 
OD  Z0=306/ 
Z1=267/ Z2=227 
OS  Z0=227/ 
Z1=216/ Z2=220 
Family AL 
(N.AL.) 
male 
8 19 Novel BEST1 
mutation Val9Glu 
 
10/10       10/10 N OU: central 
yellowish deposits 
stage I 
2,51/0  Altered OU, Max 
peaks: 36,4 
nV/deg
2
 (OD) and 
26,0 nV/deg
2
 (OS) 
OCT: 
OD  Z0=324/ 
Z1=264/ Z2=244  
OS  Z0=180/ 
Z1=241/ Z2=238 
 
Table I – (continued) 
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Family C 
(V.T.C.) 
Male 
NA 53 Novel BEST1 
mutation Leu234Val 
2/10    7/10 N OU: pigmented 
fibrous scarring of 
macular areas. 
Yellowish deposits 
and atrophy. 
1,15/1,17 Altered OU, Max 
peaks: 46,6 
nV/deg
2
 (OD) and 
60,8 nV/deg
2
 (OS) 
OCT: 
OD  Z0=280/ 
Z1=278/ Z2=233 
OS  Z0=143/ 
Z1=240/ Z2=195 
Family C 
(V.C.) 
Female 
12 25 Novel BEST1 
mutation Leu234Val 
8/10   8/10 N OU: central 
stationary 
scrambled egg 
lesions (1,5 mm) 
1,09/1,27 Altered OU, Max 
peaks: 88,4 
nV/deg
2
 (OD) and 
60,8 nV/deg
2
 (OS) 
OCT: 
OD  Z0=346/ 
Z1=294/ Z2=264  
OS  Z0=215/ 
Z1=292/ Z2=270 
Family C 
(V.F.C.) 
male 
7 16 Novel BEST1 
mutation Leu234Val 
2,5/10      10/10 N OU: stage III 
stationary, 
scrambled egg 
lesion and macular 
scar 
1,01/1,02 Altered OU, Max 
peaks: 96,3 
nV/deg
2
 (OD) and 
60,2 nV/deg
2
 (OS) 
OCT: 
OD  Z0=355/ 
Z1=351/ Z2=258 
OS  Z0=465/ 
Z1=408/ Z2=341 
M.J.A. 
female 
 
41 
 
 
59 No mutations in 
BEST1 
1/10           1/10 
 
 
N OU: macular hyper 
pigmentation 
affecting fovea 
1,19/0,93 NA 
 
NA 
 
S.V.M. 
female 
 
 
14 15 Novel BEST1 
mutation Glu35Lys 
4/10        < 1/10 N OD: ¾ DD centro-
macular egg yolk 
(stage II) 
OS: cicatricial lesion 
affecting fovea 
1,39/1,41 NA 
 
OCT: 
OD  Z0=374/ 
Z1=310/ Z2=258  
OS  Z0=230/ 
Z1=280/ Z2=253 
A.R.N.R. 
male 
42 
 
 
50 Pending 3/10         3/10 OU: 
Incipient 
cataract  
OU: scrambled egg 
inferior to macula 
1,50/1,42 NA 
 
OCT: 
OD  Z0=345/ 
Z1=304/ Z2=264  
OS  Z0=315/ 
Z1=292/ Z2=270 
 
 
 
Table I – (continued) 
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Family 
Patient 
Sex 
Age at 
onset 
(years) 
Age at 
examination 
DNA Visual Acuity 
OD           OS 
Biom. Fundus EOG 
Arden-
ratio 
OD/OS 
mfERG OCT 
Family DG 
(P.D.G.) 
male 
29 41 Novel BEST1 
mutation 
Glu213Gly (hh) 
10/10      2/10 N OD: stage II inferior 
to fovea 
OS: atrophic lesion 
inferior to fovea; 
disc drusen 
 1,20/1,00 Altered OU, Max 
peaks: 21,0 nV/deg
2
 
(OD) and 17,4 
nV/deg
2
 (OS) 
 
OCT: 
OD  Z0=233/ 
Z1=249/ Z2=219  
OS  Z0=229/ 
Z1=242/ Z2=214 
Family DG 
(V.D.G.) 
male 
 
30 
 
40 
Novel BEST1 
mutation 
Glu213Gly (hh) 
2/10        2/10 N OU: scrambled egg 
lesion perifoveal 
1,08/1,08 Altered OU, Max 
peaks: 16,8 nV/deg
2
 
(OD) and 31,7 
nV/deg
2
 (OS) 
NA 
 
Family DG 
(D.M.G.) 
Female 
24 24 
 
 
Novel BEST1 
mutation 
Glu213Gly (hh) 
10/10      7/10 N OD: multiple flecks 
rounding fovea; 
orange pigmented 
foveal lesion 
OS: infra-foveal 
lesion (sub-retinian 
fibrosis) + orange 
pigmented lesion 
2,65/1,45 NA 
 
NA 
 
 
Family DG 
(B.G.) 
Female 
8 13 Novel BEST1 
mutation 
Glu213Gly (Hh) 
6/10        6/10 N OU: with no 
significant 
alterations 
1,49/1,61 Altered OU, Max 
peaks: 75,7 nV/deg
2
 
(OD) and 85,4 
nV/deg
2
 (OS) 
 
OCT: 
OD  Z0=199/ 
Z1=277/ Z2=239 
OS  Z0=180/ 
Z1=277/ Z2=236 
Family Alm. 
(J.E.A.) 
male 
28 32 Pending 3/10         4/10 OD: mild 
subcapsular 
lens 
opacification 
OS: N 
OU: yellowish 
centromacular 
deposits 
1,25/1,16 Altered OU, Max 
peaks: 36,3 nV/deg
2
 
(OD) and 13 nV/deg
2
 
(OS) 
 
OCT: 
OD  Z0=294/ 
Z1=365/ Z2=398 
OS  Z0=341/ 
Z1=403/ Z2=406 
Table II – Clinical data and mutations involved for the patients with ARB presented in this study 
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Family 
Patient 
Sex 
Age at 
onset 
(years) 
Age at 
examination 
DNA Visual Acuity 
OD           OS 
Biom. Fundus EOG 
Arden-
ratio 
OD/OS 
mfERG OCT 
Family T. 
(J.L.T.) 
male 
 
50 
 
 
57 No mutations in 
BEST1  
1/10         6/10 OD: N 
OS: 
subcapsular 
posterior 
cataract 
OD: 
hipopigmented 
atrophic macular 
area 
OS: dispersed egg 
yolk lesions 
1,73/1,84 
(both 
border- 
line) 
Altered OU, Max 
peaks: 32,3nV/deg2 
(OD) e 35,3nV/deg
2
 
(OS) 
OCT: 
OD  Z0=182/ 
Z1=270/ Z2=243 
OS  Z0=193/ 
Z1=290/ Z2=249 
Family S. 
(J.L.S.) 
male 
 
 
33 
 
 
46 Pending 10/10       10/10 N OU: yellowish 
extra-fovea 
lesions of 
multifocal Best 
1,13/1,34 Altered OU, Max 
peaks: ~65,4nV/deg
2 
(OD) e 76,3nV/deg
2
 
(OS) 
OCT: 
OD  Z0=218/ 
Z1=283/ Z2=244 
OS  Z0=221/ 
Z1=283/ Z2=241 
Table III – Clinical data and mutations involved for the patients with multifocal Best presented in this study 
OD – right eye; OS – left eye; OU – both eyes; Biom. – Biomicroscopy; EOG – Electro-oculogram; mfERG – multifocal Electroretinogram; OCT – Optical 
Coherence Tomography; N – normal; NA – not available; stage I – pre-viteliform stage; stage II – vitelliform stage; stage III – pseudohypopyon stage. 
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Electrophysiological findings 
Typical EOG findings, with a reduction in the EOG light rise, were shown in most 
patients. In the BVMD sub-group we found reduced Arden ratios in all families However, 
these values were extremely reduced in family C, within the range normally found for the 
ARB phenotype (Burgess et al, 2008). Family D.G., with a confirmed molecular diagnosis 
compatible with ARB also showed Arden ratio values well below the limits, compared with 
most BVMD families (Table I and II). 
In all affected individuals, clinical electrophysiology demonstrated abnormal 
multifocal ERGs. There was a substantial reduction in mfERG amplitude responses in BVMD 
patients when compared with controls (Fig. 10 and 11 for both N1 and P1 components). 
With regard to the N1 and P1 mfERG components, amplitudes were found to be dramatically 
reduced for all rings in BVMD patients. Maximum peaks in mfERG responses ranged from a 
minimum value of 11 nV/deg2 (recorded in the left eye of the youngest affected member of 
family A) to 96,3 nV/deg2 (recorded in the right eye of the youngest member of family C). 
Intrafamilial heterogeneity is observed, especially in family AL, where amplitude reduction of 
maximum peaks does not seem to be age-dependent. Abnormal mfERG responses were 
found for all tested eccentricities, though effect size was clearly smaller for more peripheral 
rings. 
In the ARB sub-group of patients, maximum peaks on mfERG ranged from a minimum 
of 16,8 nV/deg2 and 31,7 nV/deg2; it should be underscored that the heterozygous carrier 
(Figure5, III-1) also revealed subnormal peaks ranging from 75,7 nV/deg2 and 85,4 nV/deg2 
with no eccentricity. 
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Fig. 10 – mfERG recordings in BVMD patients (see Table I for recorded data). A: patient H. AL. 
with a central egg-yolk lesion (OD) and scrambled egg and atrophic scarring (OS). B: J.G. with 
later age at onset, normal OD and a cicatricial perifoveal lesion (OS). 
A 
B 
Fig. 11 – mfERG recordings in an ARB patient (see Table II for recorded data). a: patient P.D.G. 
with a lesion in stage II (OD) and an atrophic lesion (OS) inferior to fovea.  
a 
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For the 2 patients with multifocal Best disease, peak amplitudes were below normal; 
however, since only 2 isolated cases were analyzed the differences observed may represent 
the normal course of disease. 
 
OCT findings 
Representative images from OCT imaging are shown in Figure 12, 13 and 14. OCT 
images acquired through the fovea showed heterogeneity, from preserved central foveal 
depression and mild thickness increase of the retina to loss of central foveal depression, 
detachment of RPE and substantial thickness increase of the retina. OCT showed a 
hyporreflective structure beneath retina and RPE that is compatible with the lipofuscin 
material. Consequently, the superficial layers of the retina appeared thinned and severely 
altered. Thickness values for Z0 correlated well with the fundus images and disease stages, 
for all patients in the 3 sub-groups. However, no correlation was observed between OCT 
central thickness and BCVA; usually very low BCVA values are seen in more severely affected 
individuals that present central macular atrophic/scarring lesions with near normal thickness 
on OCT but disorganized structure. 
None of the affected individuals of our cohort displayed changes compatible with 
choroidal neovascularization on OCT imaging. 
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OD OS 
OD OS 
Fig. 12 – OCT recordings in BVMD patients (see Table I for recorded data). A: patient S.V.M. with 
loss of central foveal depression and substantial increased thickness of the retina (OU). B: V.C. 
with loss of central foveal depression and substantial increased thickness of the retina. 
A 
B 
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OD OD 
a b 
Fig. 13 – OCT recordings in ARB patients (see Table II for recorded data). a: patient B.D.G. (Fig. 5 
– III:1)  near normal total retinal thickness for all rings; the RPE layer is thicker across this section 
(heterozygous carrier)  b: P.D.G (Fig. 5 – II:2) significant disorganization of all retinal layers, with 
cystic formations above and within the RPE layer in an homozygous affected ARB patient. 
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Discussion 
 
Best Disease is known to have variable penetrance and expressivity. In the present 
study this heterogeneity is observed even in patients within the same family. Many patients 
maintain a good visual acuity for decades, which may lead to later diagnosis of the disease. 
In fact, the diagnosis of many variants of the BEST1 related clinical continuum, especially the 
milder forms may be diagnosed as part of a routine “normal” eye exam. In Family C. (Table I) 
was identified a novel BEST1 mutation Leu234Val, with autosomal dominant inheritance 
(Fig. 4). The affected members of this family show an extremely low EOG (Arden ratio 
between 1,01 and 1,27), moderate alterations in mfERG and fundus photography with 
advanced stage lesions early in life. However, their VA is generally preserved. The apparent 
low vision of the right eye (patient VFC) seems to be a consequence of uncorrected 
refractive amblyopia, unrelated with BVMD. The vision loss observed in the older individual 
of this family simply reflects the normal course of disease.   
  Late-onset symptoms are not uncommon and these individuals with BEST1 
mutations, even if they already have electrophysiologic and morphologic alterations, could 
be undiagnosed or later diagnosed. In some cases, the decrease of VA with the duration of 
the disease may be due to environmental or genetic factors. These modifiers can be another 
explanation for the decreased penetrance and variable expressivity in BEST1 associated 
phenotypes (Boon et al., 2009). 
In this paper we also study families with autosomal recessive bestrophinopathy, like 
family DG and another isolated case with unknown family history. Family DG was previously 
defined as a Best-like case, with autosomal-dominant ocular phenotypes. The affected 
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members of this family show vitelliform lesions characteristic of Best disease on fundus 
photography, contrary to Burgess’ conclusions (Burgess et al., 2008). They also have low 
Arden ratios on EOG and considerable alterations on mfERG. Molecular findings revealed a 
novel BEST1 mutation Glu213Gly in homozygous state in three patients of family DG and in 
heterozygous state in two cousins (Fig. 5 – III:1 and III:2). It should be underscored that this 
is the first Portuguese family described with this phenotype and confirmed from a molecular 
standpoint. The homozygote patients show an extremely low Arden ratio and also 
abnormalities on mfERG. Their visual acuity seems to be related with lower EOG. The 
heterozygote boy was confirmed to be carrier but he had no sign of disease. On the other 
hand, the heterozygote girl (B.D.G., Fig. 5 – III:1 and Table II) had an abnormal EOG (Arden 
ratio 1,49 OD; 1,61 OS), altered mfERG and a mild thickness increase of the retina (central 
foveal depression was preserved). This findings contrast with the fundus photography that 
showed no significant alterations. Consanguinity is highly probable since both sides of the 
family originate from a small isolated village. 
Our results indicate that a strict classification in stages is too rigid, because many of 
the BVMD lesions show aspects of different stages (Boon et al., 2009). Most BVMD lesions 
remain stationary after a considerable follow-up period, but our study also illustrates that a 
minority of lesions may show notable stage changes within less than a year. 
The present study provides new insights into structure-function correlations at the 
level of the neurosensory retina in BVMD, including the involvement of the central and 
peripheral cone pathways, and their relationship with clinical markers of disease 
progression. Accordingly, our work confirmed that BMD patients have neurosensory retina 
dysfunction up to 30°, as shown by reduced mfERG peak amplitudes. This functional 
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impairment, which, according to Hood (Hood, 2000) can be speculated to be attributed to 
either cone photoreceptor cell loss or damage to the cone outer segments (Scholl, et al., 
2002; Schatz, et al., 2006; Glybina, et al., 2006). There is a pan-retinal defect in BVMD 
corroborated by the recently reported abundant expression of (mutated) bestrophin in the 
peripheral retina and of global retinal pigment epithelial failure (as obtained by the 
commonly altered EOG measures) (O'Gorman, et al., 1988; Maloney, et al., 1977; Mullins, et 
al., 2007; Marmor, et al., 1993; Seddon, et al., 2003). We believe that the extension of retinal 
damage and the familial intravariability and intervariability of age of onset and range of 
visual loss are part of a scenario of variable expression in BVMD. 
In our study there is no reference of choroidal neovascularization, which allow us to 
conclude that it is rare in this type of retinal dystrophy, in agreement with other findings in 
the literature. 
In conclusion, the definitive diagnosis of Best Vitelliform Macular Dystrophy and 
Autosomal Recessive Bestrophinopathy are best based on molecular genetics. Phenotypical 
analysis is essential to identify the role of RPE functional changes in the determination of the 
clinical diagnosis. Genotype-phenotype correlations allow us to better understand the 
pathophysiology of RPE related diseases. 
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